MetLife Investment Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

MetLife Investment Management’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-23,409	Closed	-$178K	–	2918
2022 Q1	$178K	Buy	23,409 +8,450	+56%	+$80.1K	﹤0.01%	2420
2021 Q4	$153K	Buy	14,959 +5,019	+50%	+$64K	﹤0.01%	2217
2021 Q3	$133K	Sell	9,940 -5,754	-37%	-$93.8K	﹤0.01%	2306
2021 Q2	$344K	Hold	15,694	–	–	﹤0.01%	1797
2021 Q1	$378K	Hold	15,694	–	–	﹤0.01%	1684
2020 Q4	$282K	Hold	15,694	–	–	﹤0.01%	1798
2020 Q3	$181K	Hold	15,694	–	–	﹤0.01%	1914
2020 Q2	$381K	Hold	15,694	–	–	﹤0.01%	1526
2020 Q1	$173K	Hold	15,694	–	–	﹤0.01%	1781
2019 Q4	$415K	Hold	15,694	–	–	﹤0.01%	1562
2019 Q3	$358K	Hold	15,694	–	–	﹤0.01%	1597
2019 Q2	$481K	Buy	15,694 +6,039	+63%	+$127K	0.01%	1502
2019 Q1	$160K	Hold	9,655	–	–	﹤0.01%	2095
2018 Q4	$185K	Hold	9,655	–	–	﹤0.01%	1955
2018 Q3	$505K	Hold	9,655	–	–	0.01%	1543
2018 Q2	$420K	Buy	9,655 +3,123	+48%	+$134K	0.01%	1512
2018 Q1	$242K	Buy	+6,532	New	+$174K	﹤0.01%	1786

Other funds holding GTHX

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MetLife Investment Management's GTHX Position: Q2 2022 in Review

MetLife Investment Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2022, closing a stake of 23,409 shares — an estimated $178K sold.

MetLife Investment Management first reported a position in GTHX in Q1 2018 and held it in 17 quarters. The position peaked at $505K in Q3 2018. 98 funds tracked by Wall St. Rank hold GTHX as of Q2 2022.

MetLife Investment Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
MetLife Investment Management sold 23,409 G1 Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $178K.
MetLife Investment Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2018 and held it in 17 quarters.
MetLife Investment Management's G1 Therapeutics, Inc. Common Stock position peaked at $505K in Q3 2018.
98 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2022.

Based on MetLife Investment Management's 13F filing for Q2 2022, filed 11 Aug 2022.